Pfizer Updates Haleon Stake in SC 13D/A Amendment No. 5

TL;DR

**Pfizer just updated its Haleon ownership, keeping investors in the loop.**

AI Summary

Pfizer Inc. filed an Amendment No. 5 to its Schedule 13D on January 19, 2024, regarding its ownership in Haleon plc. This filing updates previous disclosures about Pfizer's stake in Haleon, specifically concerning Ordinary Shares and American Depositary Shares (ADSs). This matters to investors because it provides current information on a significant shareholder's position, which can influence market perception and potentially future stock movements of Haleon.

Why It Matters

This filing provides transparency on Pfizer's continued ownership in Haleon, which can impact investor sentiment and trading activity for Haleon's stock.

Risk Assessment

Risk Level: low — This is a routine update to a previous filing and does not indicate any immediate significant risk or change in strategy.

Analyst Insight

Investors should note this as a routine update from a major shareholder. While not indicating an immediate change in strategy, it's a data point for tracking Pfizer's long-term involvement with Haleon. No immediate action is suggested based solely on this administrative update.

Key Numbers

• 0000078003-24-000010 — Accession Number (Unique identifier for this specific SEC filing.)
• 0001900304 — Haleon plc's CIK (Central Index Key for Haleon plc, used to identify the company in SEC filings.)
• 0000078003 — Pfizer Inc.'s CIK (Central Index Key for Pfizer Inc., used to identify the company in SEC filings.)
• 405552100 — CUSIP Number (Identifier for Haleon plc's Ordinary Shares and American Depositary Shares.)
• 5 — Amendment Number (This is the fifth amendment to the original Schedule 13D filing by Pfizer regarding Haleon.)

Key Players & Entities

• Pfizer Inc. (company) — the filing person and a significant shareholder of Haleon plc
• Haleon plc (company) — the subject company whose securities are being reported
• Margaret M. Madden, Esq. (person) — Senior Vice President and Corporate Secretary, Chief Governance Counsel for Pfizer Inc.
• Jacob A. Kling, Esq. (person) — Wachtell, Lipton, Rosen & Katz, counsel for Pfizer Inc.
• January 16, 2024 (date) — Date of Event which Requires Filing of this Statement

Forward-Looking Statements

• Pfizer will continue to periodically update its Haleon stake through further 13D/A filings as its ownership percentage changes. (Pfizer Inc.) — high confidence, target: Ongoing

FAQ

From the Filing

0000078003-24-000010.txt : 20240119 0000078003-24-000010.hdr.sgml : 20240119 20240119162019 ACCESSION NUMBER: 0000078003-24-000010 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Haleon plc CENTRAL INDEX KEY: 0001900304 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-93722 FILM NUMBER: 24545848 BUSINESS ADDRESS: STREET 1: BUILDING 5, FIRST FLOOR STREET 2: THE HEIGHTS CITY: WEYBRIDGE STATE: X0 ZIP: KT13 0NY BUSINESS PHONE: 44 1932 822000 MAIL ADDRESS: STREET 1: BUILDING 5, FIRST FLOOR STREET 2: THE HEIGHTS CITY: WEYBRIDGE STATE: X0 ZIP: KT13 0NY FORMER COMPANY: FORMER CONFORMED NAME: DRVW 2022 Ltd DATE OF NAME CHANGE: 20211217 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 SC 13D/A 1 a13d-a_12024hln.htm SC 13D/AMENDMENT_ 5 HALEON PLC Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc. 66 Hudson Boulevard East New York, New York 10001-2192 (212) 733-2323 Copy to: Jacob A. Kling, Esq. Wachtell, Lipton, Rosen & Katz 51 West 52nd Street New York, New York 10019 (212) 403-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 16, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. *    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). **    This CUSIP applies to the Issuer’s American Depositary Shares, each representing two Ordinary Shares. No CUSIP has been assigned to the Ordinary Shares. 1 NAMES OF REPORTING PERSONS Pfizer Inc. (“ Pfizer ” or the “ Reporting Person ”) 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ 3 SEC USE ONLY 4 SOURCE OF FUND